Carbamazepine for schizophrenia

Abstract

Background Many people with schizophrenia do not achieve a satisfactory treatment response with just antipsychotic drug treatment and various adjunct medications are used to promote additional response. The antiepileptic carbamazepine is one such drug. Objectives To evaluate the effects of carbamazepine and its derivatives for the treatment of schizophrenia and related psychoses.

Schizoaffective disorder–an ongoing challenge for psychiatric nosology

“…However, the comparability of these results is limited by the use of different diagnostic criteria for schizoaffective disorder. Furthermore, recent Cochrane reviews found no clear empirical evidence for the efficacy of lithium [63], carbamazepine [64] or valproate [8].…”

Schizoaffective disorder–an ongoing challenge for psychiatric nosology

“…However, the comparability of these results is limited by the use of different diagnostic criteria for schizoaffective disorder. Furthermore, recent Cochrane reviews found no clear empirical evidence for the efficacy of lithium [63], carbamazepine [64] or valproate [8].…”

Treatment of schizoaffective disorder – a challenge for evidence‐based psychiatry

“…conceded that it is not possible to establish a strategy for the long‐term treatment of schizoaffective disorder on the basis of high‐level research. The lack of empirical evidence of the efficacy of lithium, carbamazepine and valproate is mentioned in recent Cochrane reviews (59–61).…”

Antipsychotics, mood stabilisers, and risk of violent crime

“…This finding is important because coadministration of antipsychotics and mood stabilisers is common in psychiatry 53,54 despite an uncertain evidence base. 25,45,55 For example, one US regional survey showed that 47% of 8405 inpatients diagnosed with schizophrenia received a mood stabiliser. 56 One concern about polypharmacy is the risk of side-effects, especially metabolic ones, in patients with schizophrenia.…”

Schizoaffective disorder–an ongoing challenge for psychiatric nosology

“…However, the comparability of these results is limited by the use of different diagnostic criteria for schizoaffective disorder. Furthermore, recent Cochrane reviews found no clear empirical evidence for the efficacy of lithium [63], carbamazepine [64] or valproate [8].…”

Treatment of schizoaffective disorder – a challenge for evidence‐based psychiatry

“…conceded that it is not possible to establish a strategy for the long‐term treatment of schizoaffective disorder on the basis of high‐level research. The lack of empirical evidence of the efficacy of lithium, carbamazepine and valproate is mentioned in recent Cochrane reviews (59–61).…”

Antipsychotics, mood stabilisers, and risk of violent crime

“…This finding is important because coadministration of antipsychotics and mood stabilisers is common in psychiatry 53,54 despite an uncertain evidence base. 25,45,55 For example, one US regional survey showed that 47% of 8405 inpatients diagnosed with schizophrenia received a mood stabiliser. 56 One concern about polypharmacy is the risk of side-effects, especially metabolic ones, in patients with schizophrenia.…”

Schizoaffective disorder–an ongoing challenge for psychiatric nosology

“…However, the comparability of these results is limited by the use of different diagnostic criteria for schizoaffective disorder. Furthermore, recent Cochrane reviews found no clear empirical evidence for the efficacy of lithium [63], carbamazepine [64] or valproate [8].…”

Treatment of schizoaffective disorder – a challenge for evidence‐based psychiatry

“…conceded that it is not possible to establish a strategy for the long‐term treatment of schizoaffective disorder on the basis of high‐level research. The lack of empirical evidence of the efficacy of lithium, carbamazepine and valproate is mentioned in recent Cochrane reviews (59–61).…”

Antipsychotics, mood stabilisers, and risk of violent crime

“…This finding is important because coadministration of antipsychotics and mood stabilisers is common in psychiatry 53,54 despite an uncertain evidence base. 25,45,55 For example, one US regional survey showed that 47% of 8405 inpatients diagnosed with schizophrenia received a mood stabiliser. 56 One concern about polypharmacy is the risk of side-effects, especially metabolic ones, in patients with schizophrenia.…”